GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to
determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in
combination in patients with Type 2 diabetes. This is the first study to determine whether
the study medications have a positive benefit for subjects on their cholesterol levels, body
weight, liver fat content and other metabolic parameters compared with a placebo medication.